이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NantHealth 과거 수익 실적

과거 기준 확인 0/6

NantHealth은 연평균 24.2%의 비율로 수입이 증가해 온 반면, Healthcare Services 산업은 연평균 8.3%의 비율로 수입이 증가했습니다. 매출은 연평균 7.1%의 비율로 감소했습니다.

주요 정보

24.2%

수익 성장률

26.6%

EPS 성장률

Healthcare Services 산업 성장	1.7%
매출 성장률	-7.1%
자기자본 수익률	n/a
순이익	-109.5%
최근 수익 업데이트	30 Sep 2023

최근 과거 실적 업데이트

Recent updates

Investors Aren't Buying NantHealth, Inc.'s (NASDAQ:NH) Revenues

Apr 17

NantHealth GAAP EPS of -$0.11, revenue of $16.5M

Aug 04

Ronald Louks Is The Chief Operating Officer of NantHealth, Inc. (NASDAQ:NH) And They Just Sold 26% Of Their Shares

Mar 18

Time To Worry? Analysts Are Downgrading Their NantHealth, Inc. (NASDAQ:NH) Outlook

Mar 06

If You Had Bought NantHealth (NASDAQ:NH) Shares A Year Ago You'd Have Earned 183% Returns

Feb 04

NantHealth jumps after study highlights the utility of its decision-support platform

Dec 11

수익 및 비용 분석

NantHealth 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OTCPK:NHIQ 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 23	64	-70	55	19
30 Jun 23	68	-69	63	23
31 Mar 23	68	-64	64	22
31 Dec 22	67	-68	63	23
30 Sep 22	66	-59	60	23
30 Jun 22	63	-56	57	21
31 Mar 22	63	-59	55	20
31 Dec 21	63	-58	52	20
30 Sep 21	65	-62	49	19
30 Jun 21	70	-62	48	19
31 Mar 21	71	-95	49	19
31 Dec 20	73	-88	49	17
30 Sep 20	73	-81	50	16
30 Jun 20	73	-86	51	14
31 Mar 20	75	-55	53	14
31 Dec 19	77	-65	56	14
30 Sep 19	82	-101	57	16
30 Jun 19	85	-183	61	17
31 Mar 19	87	-188	65	20
31 Dec 18	89	-190	71	21
30 Sep 18	89	-164	77	25
30 Jun 18	88	-89	77	28
31 Mar 18	90	-125	78	30
31 Dec 17	87	-131	75	34
30 Sep 17	82	-157	71	36
30 Jun 17	81	-161	75	38
31 Mar 17	80	-138	95	46
31 Dec 16	80	-145	105	47
30 Sep 16	83	-131	105	39
30 Jun 16	77	-128	102	36
31 Mar 16	66	-110	80	25
31 Dec 15	46	-62	56	14
30 Sep 15	48	-84	66	21
30 Jun 15	43	-91	62	18
31 Mar 15	39	-86	53	17
31 Dec 14	34	-84	46	17
31 Dec 13	27	-41	35	11

양질의 수익: NHIQ 은(는) 현재 수익성이 없습니다.

이익 마진 증가: NHIQ 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NHIQ 은(는) 수익성이 없지만 지난 5년 동안 연간 24.2% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 NHIQ 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: NHIQ 은(는) 수익성이 없어 지난 해 수익 성장을 Healthcare Services 업계( 8.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: NHIQ 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

NantHealth 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Recent updates

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Investors Aren't Buying NantHealth, Inc.'s (NASDAQ:NH) Revenues

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth GAAP EPS of -$0.11, revenue of $16.5M

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS misses analyst expectations

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$3.25

Consensus EPS estimates fall by 18%

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: EPS exceeds analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Chief Operating Officer notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

Consensus EPS estimates fall to -US$0.52

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought US$5.0m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Ronald Louks Is The Chief Operating Officer of NantHealth, Inc. (NASDAQ:NH) And They Just Sold 26% Of Their Shares

Chief Operating Officer recently sold US$297k worth of stock

Time To Worry? Analysts Are Downgrading Their NantHealth, Inc. (NASDAQ:NH) Outlook

Analysts lower EPS estimates to -US$0.52

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue and earnings miss expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

If You Had Bought NantHealth (NASDAQ:NH) Shares A Year Ago You'd Have Earned 183% Returns

New 90-day high: US$4.07

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: US$3.67

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth jumps after study highlights the utility of its decision-support platform

New 90-day high: US$2.81

Price target lowered to US$3.75

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Third quarter 2020 earnings released: US$0.099 loss per share

Revenue beats expectations, earnings disappoint

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.01

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low: US$2.39

New 90-day low - US$2.60

Analysts lower EPS estimates to -US$0.55

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

수익 및 비용 분석